Drug Search Results
More Filters [+]

Capsaicin

Alternative Names: capsaicin, qutenza, ngx-4010, ngx-1998, ausanil, algrx 4975, cntx-4975, cntx4975, cntx 4975, dfs 1.5%/ms 25%/menth 6%/cap 0.025% pak, dfs 75mg dr/ms 25%/menth 6%/cap 0.025% pak, pennsaicin, iclofenac cp, dicloheal-60, capsfenac pak, ziclopro, nudiclo solupak, nudiclo tabpak, nudroxipak i-800, nudroxipak m-15, nudroxipak n-500, nudroxipak dsdr-50, nudroxipak dsdr-75, nudroxipak e-400, inavix
Latest Update: 2024-06-06
Latest Update Note: Clinical Trial Update

Product Description

Capsaicin is a capsaicinoid. It has a role as a non-narcotic analgesic, a voltage-gated sodium channel blocker and a TRPV1 agonist. Capsaicin is a chili pepper extract with analgesic properties. Capsaicin is a neuropeptide releasing agent selective for primary sensory peripheral neurons. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Capsaicin)

Mechanisms of Action: TRPV1 Agonist,GABA Modulator

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Topical,Transdermal

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | India | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: NeurogesX
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Capsaicin

Countries in Clinic: France, Netherlands, Poland, Spain, Sweden, United Kingdom, United States

Active Clinical Trial Count: 6

Highest Development Phases

Phase 3: Breast Cancer|Chemotherapy-induced Peripheral Neuropathy|Neuralgia|Neuropathic Pain|Peripheral Nervous System Diseases

Phase 2: Animal Hypersensitivity|Asthma|Chronic Cough|Chronic Pain|Environmental Hypersensitivity|Evans Syndrome|Fish Hypersensitivity|Food Hypersensitivity|Labor Pain

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CAPNEUCHIM

P3

Not yet recruiting

Chemotherapy-induced Peripheral Neuropathy|Peripheral Nervous System Diseases

2027-03-01

AV001

P3

Recruiting

Neuropathic Pain|Neuralgia

2024-10-01

95%

NCT04125563

P2

Active, not recruiting

Chronic Cough|Asthma|Food Hypersensitivity|Chronic Pain|Evans Syndrome|Fish Hypersensitivity|Labor Pain|Animal Hypersensitivity|Environmental Hypersensitivity|Neuropathic Pain

2024-06-30

2021-001409-64

P3

Active, not recruiting

Neuropathic Pain

2024-01-10

Recent News Events